Trial Profile

Assessment of the Effects and Tolerability of RD03/2016 (Levofloxacin; Ketorolac Trometamol 0.5+0.5% w/v Eye Drops Solution) for the Treatment of Bacterial Conjunctivitis in Adults: a Multicentre, Randomized, Blinded-assessor, Phase II Non Inferiority Study - MIRAKLE

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ketorolac/trometamol (Primary) ; Levofloxacin (Primary) ; RD 03 2016 (Primary)
Indications Bacterial conjunctivitis
Focus Therapeutic Use
Acronyms MIRAKLE
Sponsors NTC

05 Dec 2024 Interim Results presented in the NTC Media Release.
05 Dec 2024 According to a NTC media release, company aims to finalize the commercial partnering for this asset in most countries of the world before end of 2025.
05 Dec 2024 Interim results published in the NTC Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com